| Literature DB >> 35630608 |
Mahesh Attimarad1, Katharigatta Narayanaswamy Venugopala1,2, Muhammad S Chohan3, Marysheela David4, Efren Ii Plaza Molina5, Nagaraja Sreeharsha1,6, Anroop Balachandran Nair1, Christophe Tratrat1, Abdulrahman Ibrahim Altaysan1, Abdulmalek Ahmed Balgoname1.
Abstract
A rapid and reproducible hydrophilic liquid chromatography (HILIC) process was established for concomitant determination of remogliflozin etabonate (RE), vildagliptin (VD), and metformin (MF) in a formulation. A face-centered central composite experimental design was employed to optimize and predict the chromatographic condition by statistically studying the surface response model and design space with desirability close to one. A HILIC column with a simple mobile phase of acetonitrile (65% v/v) and 20 mM phosphate buffer (35% v/v, pH 6, controlled with orthophosphoric acid) was used to separate RE, VD, and MF. RE, VD, and MF were separated in 3.6 min using an isocratic mode mobile phase flow at a flow rate of 1.4 mL at room temperature, and the analytes were examined by recording the absorption at 210 nm. The developed HILIC method was thoroughly validated for all parameters recommended by ICH, and linearity was observed in the ranges 20-150 µg/mL, 10-75 µg/mL, and 50-750 µg/mL for RE, VD, and MF, respectively, along with excellent regression coefficients (r2 > 0.999). The calculated percentage relative deviation and relative error ascertained the precision and accuracy of the method. The selectivity and accuracy were further confirmed by the high percentage recovery of added standard drugs to the formulation using the standard addition technique. The robustness of the HILIC processes was confirmed by developing a half-normal probability plot and Pareto chart, as the slight variation of a single factor had no significant influence on the assay outcomes. Utilization of the optimized HILIC procedure for concurrent quantification of RE, VD, and MF in solid dosage forms showed accurate and reproducible results. Hence, the fast HILIC method can be regularly employed for the quality assurance of pharmaceutical preparations comprising RE, VD, and MF.Entities:
Keywords: HILIC; chromatography; metformin; optimization; quality by design; remogliflozin; validation; vildagliptin
Mesh:
Substances:
Year: 2022 PMID: 35630608 PMCID: PMC9148089 DOI: 10.3390/molecules27103135
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.927
Figure 1Chemical structures of metformin (A), vildagliptin (B), and remogliflozin (C).
Seventeen experiments suggested by face-centered CCD for the optimization of chromatographic conditions.
| Pattern-Coded Value | Run | Factor 1: Percentage | Factor 2: pH | Factor 3: Flow Rate | Resolution | Resolution |
|---|---|---|---|---|---|---|
| + + + | 1 | 70 | 6.5 | 1.4 | 5.76 | 39.29 |
| − − + | 2 | 60 | 5.5 | 1.4 | 9.90 | 4.81 |
| 0 0 0 | 3 | 65 | 6 | 1.2 | 9.74 | 13.32 |
| 0 0 0 | 4 | 65 | 6 | 1.2 | 9.62 | 12.98 |
| 0 0 0 | 5 | 65 | 6 | 1.2 | 9.48 | 13.93 |
| + − − | 6 | 70 | 5.5 | 1 | 8.64 | 16.77 |
| 0 + 0 | 7 | 65 | 6.5 | 1.2 | 5.50 | 13.30 |
| 0 − 0 | 8 | 65 | 5.5 | 1.2 | 4.08 | 0.81 |
| − − − | 9 | 60 | 5.5 | 1 | 5.63 | 1.11 |
| 0 0 0 | 10 | 65 | 6 | 1.2 | 9.82 | 12.41 |
| 0 0 − | 11 | 65 | 6 | 1 | 9.77 | 17.57 |
| − + + | 12 | 60 | 6.5 | 1.4 | 8.74 | 1.69 |
| − + − | 13 | 60 | 6.5 | 1 | 8.63 | 12.09 |
| + 0 0 | 14 | 70 | 6 | 1.2 | 10.98 | 39.38 |
| − 0 0 | 15 | 60 | 6 | 1.2 | 11.54 | 4.15 |
| + + − | 16 | 70 | 6.5 | 1 | 9.48 | 59.01 |
| + − + | 17 | 70 | 5.5 | 1.4 | 9.00 | 3.26 |
| 0 0 + | 18 | 65 | 6 | 1.4 | 10.43 | 7.89 |
Polynomial equation coefficients with corresponding p-values for peak resolution.
| Coefficient Terms | Resolution between RE and VD (RS1) | Resolution between VD and MF (RS2) | ||
|---|---|---|---|---|
| Coefficient Value | Coefficient Value | |||
| Constant | +9.24 | <0.0001 | +1427.372 | <0.0001 |
| ACN a | −0.058 | 0.7451 | −61.984 | <0.0001 |
| pH | +0.086 | 0.6309 | +88.987 | <0.0001 |
| Flow rate | +0.168 | 0.3571 | +337.112 | 0.0026 |
| ACN × pH | −0.529 | 0.0252 | +3.520 | 0.0001 |
| ACN × flow rate | −0.967 | 0.0010 | −3.317 | 0.0327 |
| pH × flow rate | −1.03 | 0.0007 | −25.406 | 0.0837 |
| ACN2 | +2.19 | 0.0002 | +0.365 | 0.0033 |
| pH2 | −4.28 | <0.0001 | −22.299 | 0.0357 |
| Flow rate2 | +1.03 | 0.0145 | −2.570 | 0.9640 |
a Amount of acetonitrile in the mobile phase.
Figure 2Perturbation plots showing the effect of the concentration of acetonitrile (A), pH of the mobile phase (B), and flow rate (C) on the resolutions of RE−VD (a) and VD−MF (b).
Figure 3The 3D response surface models showing the effect of concentration of acetonitrile (A), pH of the mobile phase (B), and flow rate (C) on the resolutions of RE−VD (a–c) and VD−MF (d–f).
Figure 4Diagnostic plots for resolutions of RE−VD (a) and VD−MF (b) showing the comparison of actuals, against predicted resolution values.
Figure 5Overlay plot of chromatographic conditions suggested by the model. ACN: percentage acetonitrile; FR: flow rate.
Figure 6Representative chromatograms of standard solution (A) and formulation solution (B). Retention times: RE = 1.5 min, VD 2.3 = min, and MF = 3.5 min.
System suitability and regression analysis results.
| Parameters | RE | VD | MF |
|---|---|---|---|
| System suitability results | |||
| Retention time ± SD | 1.51 ± 0.021 | 2.35 ± 0.029 | 3.54 ± 0.065 |
| Peak area ± SD | 5765.5 ± 46.84 a | 824.29 ± 7.34 b | 9678.47 ± 85.75 c |
| Resolution ± SD | - | 7.85 ± 0.05 d | 10.40 ± 0.08 e |
| Tailing factor ± SD | 1.12 ± 0.022 | 1.05 ± 0.013 | 1.15 ± 0.023 |
| Theoretical plate ± SD | 7544.16 ± 65.24 | 10,908.64 ± 78.98 | 20,506.24 ± 96.47 |
| Linearity | |||
| Linearity range (µg/mL) | 20–150 | 10–75 | 50–750 |
| Slope | 57.915 | 17.171 | 50.487 |
| Intercept | 48.462 | −46.048 | −237.84 |
| Regression coefficient ( | 0.9992 | 0.9988 | 0.9997 |
| Sensitivity | |||
| DL (µg/mL) | 4.73 | 2.81 | 1.48 |
| QL (µg/mL) | 14.34 | 8.54 | 43.88 |
SD: standard deviation; DL: detection limit; QL: quantification limit; a 100 µg/mL; b 50 µg/mL; c 200 µg/mL; d resolution between RE and VD; e resolution between VD and MF.
Precision and accuracy results of the developed HILIC method.
| Drug | Within-Day | Between-Day | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Amount (µg/mL) | Amount Found Mean ( | % | % Recovery | % RE | Amount Found Mean ( | % | % Recovery | % RE | |
| RE | 20 | 19.86 ± 0.14 | 0.70 | 99.30 | −0.70 | 20.13 ± 0.23 | 1.14 | 100.65 | 0.65 |
| 75 | 74.18 ± 1.05 | 1.42 | 98.91 | −1.09 | 74.25 ± 1.35 | 1.82 | 99.00 | −1.00 | |
| 150 | 148.64 ± 2.33 | 1.57 | 99.09 | −0.91 | 147.92 ± 2.09 | 1.41 | 98.61 | −1.39 | |
| VD | 10 | 10.02 ± 0.12 | 1.20 | 100.20 | 0.20 | 9.86 ± 0.16 | 1.62 | 98.60 | −1.40 |
| 40 | 39.65 ± 0.37 | 0.93 | 99.13 | −0.88 | 39.38 ± 0.69 | 1.75 | 98.45 | −1.55 | |
| 75 | 74.24 ± 0.82 | 1.10 | 98.99 | −1.01 | 74.46 ± 1.13 | 1.52 | 99.28 | −0.72 | |
| MF | 50 | 49.16 ± 0.51 | 1.04 | 98.32 | −1.68 | 49.07 ± 0.52 | 1.06 | 98.14 | −1.86 |
| 350 | 346.73 ± 5.34 | 1.54 | 99.07 | −0.93 | 353.79 ± 4.66 | 1.32 | 101.08 | 1.08 | |
| 750 | 745.04 ± 6.79 | 0.91 | 99.34 | −0.66 | 746.21 ± 7.08 | 0.95 | 99.49 | −0.51 | |
SD: standard deviation; %RSD: percentage relative standard deviation; %RE: percentage relative error.
Figure 7Half-normal probability plots and Pareto charts showing the effect of the concentration of acetonitrile (A), pH of the mobile phase (B), flow rate (C), and wavelength of the detector (D) on the peak area of RE (a,b), VD (c,d), and MF (e,f). PA: peak area.
Assay results of formulations and percentage recovery by standard addition method.
| Label Claim | Amount Taken (µg·mL−1) | Amount Found (µg·mL−1) | % Purity | %RSD |
|---|---|---|---|---|
| Formulation 1 | VD 20 | 20.12 | 100.60 | 1.15 |
| Formulation 2 | VG 50 | 49.62 | 99.24 | 0.93 |
| Standard addition method | Recovery % | |||
| Amount of VD added (µg·mL−1) to formulation solution 1 | 10 | 10.01 | 100.10 | 0.83 |
| 20 | 19.84 | 99.20 | 1.44 | |
| 30 | 29.47 | 98.23 | 1.31 | |
| Amount of RE added (µg·mL−1) to formulation solution 1 | 20 | 19.95 | 99.75 | 1.28 |
| 40 | 39.28 | 98.20 | 1.72 | |
| 60 | 59.04 | 98.40 | 0.76 | |
| Amount of MF added (µg·mL−1) to formulation solution 1 | 100 | 98.83 | 98.83 | 1.34 |
| 200 | 198.11 | 99.06 | 1.77 | |
| 400 | 396.45 | 99.11 | 0.68 | |